SG11202105728YA - Method and compositions for treating coronavirus infection - Google Patents

Method and compositions for treating coronavirus infection

Info

Publication number
SG11202105728YA
SG11202105728YA SG11202105728YA SG11202105728YA SG11202105728YA SG 11202105728Y A SG11202105728Y A SG 11202105728YA SG 11202105728Y A SG11202105728Y A SG 11202105728YA SG 11202105728Y A SG11202105728Y A SG 11202105728YA SG 11202105728Y A SG11202105728Y A SG 11202105728YA
Authority
SG
Singapore
Prior art keywords
compositions
coronavirus infection
treating coronavirus
treating
infection
Prior art date
Application number
SG11202105728YA
Inventor
Robert A Newman
Otis C Addington
Richard Obiso
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of SG11202105728YA publication Critical patent/SG11202105728YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
SG11202105728YA 2020-03-31 2020-07-14 Method and compositions for treating coronavirus infection SG11202105728YA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US202063051576P 2020-07-14 2020-07-14
PCT/US2020/042009 WO2021201903A1 (en) 2020-03-31 2020-07-14 Method and compositions for treating coronavirus infection

Publications (1)

Publication Number Publication Date
SG11202105728YA true SG11202105728YA (en) 2021-11-29

Family

ID=77930101

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105728YA SG11202105728YA (en) 2020-03-31 2020-07-14 Method and compositions for treating coronavirus infection

Country Status (8)

Country Link
JP (2) JP7153083B2 (en)
KR (2) KR20220151038A (en)
IL (2) IL277315B (en)
MX (2) MX2020009095A (en)
RU (1) RU2020130238A (en)
SG (1) SG11202105728YA (en)
TW (2) TWI790048B (en)
WO (1) WO2021201903A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
AU2022329917A1 (en) * 2021-08-16 2024-03-07 Phoenix Biotechnology, Inc. Method and compositions for treating animal viral infections
WO2023212353A1 (en) * 2022-04-29 2023-11-02 Emory University Viral entry inhibitors derived from botanicals
CN115364136A (en) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） Application of Crassulaceae plant extract in preparing medicine for resisting novel coronavirus and influenza virus infection

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
IN165073B (en) 1986-05-13 1989-08-12 Ziya Ozel Huseyin
JPS6333341A (en) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd Treatment of glycoside
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
CN1307473A (en) 1998-05-19 2001-08-08 研究发展基金会 Triterpene compositions and methods for use thereof
CA2354037A1 (en) 1998-09-24 2000-03-30 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
EP1309605A1 (en) 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
ATE295087T1 (en) 2001-04-09 2005-05-15 Loders Croklaan Bv CONCENTRATE OF TRITERPENES
WO2002091858A1 (en) 2001-05-11 2002-11-21 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
CA2443630A1 (en) 2001-06-18 2002-12-27 S.A.V. Virex Co Ltd. Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
ES2424130T3 (en) 2004-08-13 2013-09-27 Biolase, Inc. Laser handheld instrument structure, and methods
BRPI0519948A2 (en) 2005-02-09 2009-12-01 Dabur Pharma Ltd compound, process for preparing a compound, pharmaceutical composition and method of treating cancer in a mammal
CA2603124A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006133314A2 (en) 2005-06-08 2006-12-14 Regents Of The University Of Minnesota Synthesis of betulonic and betulinic aldehydes
CA2611435C (en) 2005-06-10 2013-01-08 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101374527A (en) 2005-12-16 2009-02-25 帕纳克斯医药公司 Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
BRPI0820564A2 (en) 2007-11-13 2017-05-23 Phoenix Biotechnology Inc method for determining the likelihood of a therapeutic response in cardiac glycoside cancer chemotherapy
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
WO2009129548A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
CA2739029C (en) 2008-10-14 2018-07-10 Nerium Biotechnology, Inc. Process for extracting cardiac glycosides from plants and compositions comprising cardiac glycosides from nerium oleander
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (en) 2009-11-23 2012-06-27 张南 23-hydroxybetulinic acid derivatives as well as preparation methods and application thereof
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
MX2012007977A (en) 2010-01-11 2012-08-23 Phoenix Biotechnology Inc Method of treating neurological conditions with cardiac glycosides.
TWI386415B (en) 2010-02-02 2013-02-21 Univ Kaohsiung Medical Ursolic acid derivative and pharmaceutical composition thereof
TWI410431B (en) 2010-12-22 2013-10-01 Ind Tech Res Inst Use of oleanolic acid derivatives in the manufacture of a medicament to prevent or treat hepatitis c
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
DK2670764T3 (en) 2011-01-31 2015-12-07 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
CN102558280B (en) 2011-11-18 2014-09-17 温州大学 Method for producing 30-halogenated betulinic acid
EP2787002B1 (en) 2011-12-01 2016-06-01 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof
JP6211527B2 (en) 2011-12-01 2017-10-11 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 2-substituted oleanolic acid derivatives, their preparation and use
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2014027777A2 (en) 2012-08-14 2014-02-20 한국콜마 주식회사 Novel ursolic acid derivative and method for preparing same
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
UY35023A (en) 2012-09-10 2014-03-31 Reata Pharmaceuticals Inc DERIVATIVES C17-ALCANDIILO AND ALQUENDIILO OF THE OLEANOLIC ACID AND ITS METHODS OF USE
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
KR20150121712A (en) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
WO2017214080A1 (en) * 2016-06-09 2017-12-14 University Of Massachusetts Inhibition of zika virus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
WO2018053123A1 (en) 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
IL285232B (en) 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Compositions comprising oleandrin for treating viral infection

Also Published As

Publication number Publication date
MX2022009176A (en) 2022-08-17
TW202211926A (en) 2022-04-01
TWI790048B (en) 2023-01-11
JP2022186737A (en) 2022-12-15
MX2020009095A (en) 2022-07-28
TW202137991A (en) 2021-10-16
TWI753747B (en) 2022-01-21
WO2021201903A1 (en) 2021-10-07
KR102464428B1 (en) 2022-11-04
IL291727A (en) 2022-05-01
JP2022522074A (en) 2022-04-14
KR20220151038A (en) 2022-11-11
KR20210124010A (en) 2021-10-14
IL277315B (en) 2022-05-01
IL277315A (en) 2021-09-30
JP7153083B2 (en) 2022-10-13
IL291727B2 (en) 2023-07-01
RU2020130238A3 (en) 2022-03-14
RU2020130238A (en) 2022-03-14
IL291727B1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
IL291727A (en) Method and compositions for treating coronavirus infection
EP4100019A4 (en) Method for treating coronavirus infections
EP4093758A4 (en) Methods and compositions for treating and preventing viral infection
EP4096675A4 (en) Compositions and methods for treating long covid
EP4103164A4 (en) Compounds for treating coronavirus infection
IL299295A (en) Methods and compositions for treating hemophilia
ZA202206163B (en) Methods of treating coronavirus
GB202011871D0 (en) Composition and method
IL307872A (en) Novel compositions and methods for treating coronavirus infections
EP4114176A4 (en) Sterilization compositions and methods for using thereof
EP4103192A4 (en) Compositions and methods for treating coronavirus infections
EP4009981C0 (en) Method and compositions for treating coronavirus infection
EP4120863A4 (en) Method for treatment of coronavirus infection
EP4138862A4 (en) Compositions and methods for treating upper respiratory infections
EP4114438A4 (en) Methods and compositions for treating muscle atrophy
EP4132503A4 (en) Methods for treatment of coronavirus infections
ZA202110332B (en) Composition for treating coronavirus infection
IL277546A (en) Methods and compositions for treating coronaviral infections
GB202215010D0 (en) Compositions for preventing and treating infection
GB202205515D0 (en) Compositions for preventing and treating infection
AU2021901169A0 (en) Novel compositions and methods for treating coronavirus infections
GB202005986D0 (en) Methods and compositions for treating and combatting tuberulosis
AU2022900358A0 (en) Novel compositions and methods for treating coronavirus infections
GB202008288D0 (en) Methods and compositions for treating and combatting sars-cov and sars-cov-2
GB202005987D0 (en) Methods and compositions for treating and combatting sars-cov and sars-cov-2